Working… Menu

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02356458
Recruitment Status : Recruiting
First Posted : February 5, 2015
Last Update Posted : April 9, 2019
European Mantle Cell Lymphoma Network
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

Brief Summary:
Mantle cell lymphoma (MCL) remains an incurable disease with frequent relapses and no standard therapeutic options in case of relapse. Prolongation of remissions or induction of longer remissions is therefore crucial. Recently, a synergistic increase in the proteasomal inhibition of ibrutinib in both bortezomib-sensitive and refractory MCL cells was shown. These findings, along with the reported single agent activities of both drugs and the non-overlapping toxicities, are the rationale to combine ibrutinib and bortezomib in MCL in this trial

Condition or disease Intervention/treatment Phase
Mantle Cell Lymphoma Drug: Ibrutinib Drug: bortezomib Phase 1 Phase 2

Detailed Description:

Disease background, therapy background and aim

Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma. It represents ~5% of all lymphomas and typically is present in advanced stages, a median age of 60-65 years and a dismal prognosis with a median survival of ~3 years. Currently, it remains incurable, as the patients will relapse after first line treatment and require subsequent therapy. The disease-free survival is progressively shorter with each subsequent relapse.

Currently, there is no standard therapy for relapsed MCL patients. MCL is predominantly a disease of the elderly who are not suitable for aggressive chemotherapy. Allogeneic transplants are preferred in young and fit patients, whereas (preferably single agent) chemotherapy is used to treat older patients, but usually with short duration of responses. Recently, the therapeutic armamentarium has been expanded with the availability of novel agents targeting crucial and deregulated pathways in MCL. These include the Bruton's Kinase (BTK) inhibitor ibrutinib with excellent single agent activities. New therapeutic options in the targeted patient population are clearly needed to prolong remissions especially for elderly patients where aggressive chemotherapy and allogeneic transplants are no suitable treatment options. Recently, a synergistic increase in the proteasomal inhibition of ibrutinib in both bortezomib-sensitive and refractory MCL cells was shown.

This trial is targeting patients with diagnosis of refractory or relapsed MCL disease after pretreatment with ≤2 lines of non-bortezomib-containing chemotherapy. The proposed treatment of ibrutinib in combination with bortezomib might lead to an improvement of the therapy in the targeted relapsed/refractory patient population. Given the absence of a dose-limiting toxicity also when applied long-term, ibrutinib is well suited in this patient population as a maintenance therapy. Therefore, the combination treatment of the trial is followed by a maintenance therapy part for patients that had no disease progression. New treatment options should control the disease as best and long as possible.


Treatment consists of 6 cycles of 21 days each of ibrutinib in combination with bortezomib, followed by a maintenance therapy with ibrutinib monotherapy. In the maintenance therapy courses repeat every 28-days in the absence of disease progression or unacceptable toxicity.

Objectives Phase I The primary object of the trial is to establish the recommended phase II dose (RP2D) of ibrutinib in combination with bortezomib in patients with relapsed or refractory MCL.

The secondary objectives are

  • to determine the safety and tolerability of ibrutinib in combination with bortezomib and
  • to assess the preliminary antitumor activity of ibrutinib in combination with bortezomib Phase II The main object of the trial is to define the efficacy of the combination treatment of ibrutinib with bortezomib in patients with relapsed or refractory MCL.

The secondary objectives are

  • to determine the safety and tolerability of the RP2D and
  • to assess the efficacy of ibrutinib in combination with bortezomib in patients with relapsed MCL followed by an ibrutinib maintenance therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 73 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Actual Study Start Date : August 31, 2015
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Ibrutinib & Bortezomib
Combination therapy (trial treatment of ibrutinib in combination with bortezomib) followed by ibrutinib maintenance therapy
Drug: Ibrutinib

Combination therapy:

Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I

Maintenance therapy:

p.o daily: 560 mg

Other Name: Imbruvica

Drug: bortezomib

Combination therapy:

Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11

Other Name: Velcade®

Primary Outcome Measures :
  1. Phase I: Dose limiting toxicity (DLT) observed during the first cycle of trial treatment [ Time Frame: At day 8, 14, 21 during cycle 1 (1 cycle = 21 days) ]
    DLTs are defined based on adverse events observed in cycle 1 that are possibly, probably or definitively related to ibrutinib and/or bortezomib.

  2. Phase II: Overall response (OR) (combination therapy) [ Time Frame: 4 1/2 months after registration. ]
    OR is defined as the proportion of patients whose best overall response, is either complete response (CR), complete response unconfirmed (CRu) or partial response (PR) according to the International Working group criteria for NHL. The primary endpoint of phase II is OR observed during the combination therapy.

Other Outcome Measures:
  1. Phase I and II: Adverse events (AE) until 30 days after end of trial therapy [ Time Frame: Until 30 days after up to 2 years of trial therapy ]
    All AEs will be assessed according to NCI CTCAE v4.0

  2. Phase I: OR (combination therapy) [ Time Frame: 4 1/2 months after inclusion of each patient ]
    OR observed during the combination therapy.

  3. Phase I: OR based on best response observed during treatment (combination and maintenance therapy) [ Time Frame: Estimated at 1 1/2 years after patient registration. ]
    OR observed during the combination therapy and OR observed during trial treatment.

  4. Phase II: OR based on best response observed during treatment (combination and maintenance therapy [ Time Frame: Estimated at 1 1/2 years after patient registration. ]
    OR observed during the combination therapy and OR observed during trial treatment.

  5. Phase II: Progression-free survival (PFS) [ Time Frame: Time from patient registration to progression free survival (estimated 2 years) ]
    Time from registration until progression of disease or death as a result of any cause.

  6. Phase II: Time to treatment failure (TTF) [ Time Frame: Time from patient registration to treatment failure (estimated 2 years) ]
    Time from registration until treatment failure (due to unacceptable toxicity, progression, patient refusal, death, start of subsequent anti-MCL therapy or any other event that determines the termination of the trial treatment will be considered as treatment failure).

  7. Phase II: Duration of objective response [ Time Frame: Time from patient registration to progression/relapse (estimated 2 years). ]

    Time from first observation of CR or PR until documentation of progression, or relapse thereafter.

    Only patients with CR or a PR will be included in this analysis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient must give written informed consent before registration indicating that the patient understands the purpose of the procedures required for the trial and is willing to participate in the trial.
  • Histologically confirmed mantle cell lymphoma with either overexpression of cyclin D1 protein or evidence of t(11;14)(q13;q32) assessed by cytogenetics, by fluorescence, in situ hybridization (FISH) or by polymerase chain reaction (PCR).
  • Refractory or relapsed disease in need of systemic therapy after pretreatment with non-bortezomib-containing chemotherapy (including high-dose therapy)
  • At least one measurable lesion ≥11 mm in its greatest transverse diameter measured with CT scan (contrast enhanced) or MRI (in case of the disease cannot be adequately imaged using CT and if contrast is not appropriate for patients according to the treating physician)
  • WHO performance status 0-2
  • Age ≥ 18 years
  • Adequate hematological values:

    • Absolute neutrophil count (ANC) > 1.0 x 109/L independent of growth factor support
    • Platelets ≥ 100 x 109/L or ≥ 50 x 109/L if bone marrow involvement independent of transfusion support in either situation,
    • Hb ≥ 80 g/L
  • Adequate hepatic function:

    • Total bilirubin ≤1.5xupper limit of normal (ULN) unless bilirubin is due to Gilbert`s syndrome ≤ 5.0 x ULN
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3xULN
  • Adequate renal function: Body surface area (BSA) corrected creatinine clearance >40mL/min/1.73m2 (calculated according to the formula of Cockcroft-Gault)
  • Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the trial (see below) consistent with local regulations regarding the use of birth control methods for patients participating in clinical trials (see section 9.12). Men must agree to not donate sperm during and after the trial. These restrictions apply for

    • Ibrutinib: 3 month after the last dose of trial drug for males and 1 month for females.
    • Bortezomib: during trial treatment (for males and females): no restrictions of birth control after last dose of trial drug. Donation of sperm: 6 month after the last dose of trial drug.
  • Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [β-hCG]) or urine pregnancy test at baseline. Women who are pregnant or breastfeeding are ineligible for this trial.

Exclusion Criteria:

  • Prior therapy with ibrutinib or bortezomib
  • Adverse event neuropathy of prior therapy grade ≥2 (according to CTCAE criteria) at registration
  • Previous malignancy within 5 years with the exception of adequately treated in situ cervical cancer or localized non-melanoma skin cancer.
  • Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningeosis)
  • Evidence of ongoing systemic infections of all kind
  • Exclusion of the following prior treatments prior to trial registration

    • major surgery within 4 weeks
    • concurrent treatment with other experimental drugs or treatment in a clinical trial within 30 days.
    • treatment with chemotherapy and radiotherapy within ≥ 3 weeks
    • vaccinated with live, attenuated vaccines within 4 weeks
  • History of stroke or intracranial hemorrhage within 6 months prior to trial registration.
  • Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g. phenprocoumon)
  • Requires treatment with strong or moderate CYP3A inhibitors (see
  • Clinically significant cardiovascular disease such as congestive heart failure NYHA III or IV (as defined by the New York Heart Association Functional Classification), uncontrolled or symptomatic arrhythmias, significant QT-prolongation, unstable angina pectoris myocardial infarction within 6 months of prior to registration,
  • Known history of human immunodeficiency virus (HIV) or active Hepatitis C virus or active Hepatitis B virus infection or any uncontrolled active systemic infection requiring treatment.
  • Prior allogeneic bone marrow or solid organ transplantation
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion,

    • could impair the ability of the patient to participate in the trial
    • could compromise the patient's safety,
    • could interfere with the absorption or metabolism of ibrutinib capsules, or
    • could put the trial outcomes at undue risk
    • could prevent compliance with trial treatment.
  • Psychiatric disorder precluding understanding of trial information, giving informed consent, or interfering with compliance for oral drug intake.
  • Known hypersensitivity to trial drug(s) or hypersensitivity to any other component of the trial drugs.
  • Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information.
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial protocol and follow‐up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02356458

Layout table for location contacts
Contact: Simon Schäfer +41 31 389 91 91

Layout table for location information
Universitätsmedizin Mainz Recruiting
Mainz, Germany, 55131
Contact: Georg Hess, Prof    +49 6131 17 50 40   
Principal Investigator: Georg Hess, Prof         
Klinikum der Universität München Recruiting
München, Germany, 81377
Contact: Martin Dreyling, Prof    +49 (089) 4400 72202   
Principal Investigator: Martin Dreyling, Prof         
Universitätsmedizin Rostock Recruiting
Rostock, Germany, 18057
Contact: Sebastian Böttcher, MD    +49 381 494 7405   
Principal Investigator: Sebastian Böttcher, MD         
Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo Recruiting
Alessandria, Italy, 15100
Contact: Marco Ladetto, MD    +39 131206 262   
Principal Investigator: Marco Ladetto, MD         
European Institute of Oncology Recruiting
Milano, Italy, 20141
Contact: Corrado Tarella, Prof    +39 02-57489.538   
Principal Investigator: Corrado Tarella, Prof         
Università di Torino Recruiting
Torino, Italy, 10126
Contact: Simone Ferrero, MD    +39 011 633 4220   
Principal Investigator: Simone Ferrero, MD         
Kantonsspital Aarau Recruiting
Aarau, Switzerland, CH-5001
Contact: Mario Bargetzi, Prof    41-62-838-6053   
Principal Investigator: Mario Bargetzi, Prof         
Kantonsspital Baden Recruiting
Baden, Switzerland, 5404
Contact: Clemens Caspar, MD    +41 56 486 27 62   
Principal Investigator: Clemens Caspar, MD         
Inselspital, Bern Recruiting
Bern, Switzerland, CH-3010
Contact: Urban Novak, MD    +41 31 632 41 14   
Principal Investigator: Urban Novak, MD         
Kantonsspital Graubünden Recruiting
Chur, Switzerland, 7000
Contact: Ulrich Mey, MD    +41 81 256 71 70   
Principal Investigator: Ulrich Mey, MD         
Hopitaux Universitaires de Geneve Recruiting
Genève 14, Switzerland, 1211
Contact: Alex Friedlaender, MD    +41 22 372 29 01   
Principal Investigator: Alex Friedlaender, MD         
Centre Pluridisciplinaire d`Oncologie CHUV Recruiting
Lausanne, Switzerland, 1011
Contact: Anne Cairoli, MD    +41 (0)21 314 41 82   
Principal Investigator: Anne Cairoli, MD         
Kantonsspital Baselland Recruiting
Liestal, Switzerland, 4410
Contact: Michèle Voegeli, MD    +41 61 925 27 10   
Principal Investigator: Michèle Voegeli, MD         
Istituto Oncologico della Svizzera Italiana Recruiting
Lugano, Switzerland, CH-6900
Contact: Emanuele Zucca, Prof    +41 91 811 91 47   
Principal Investigator: Emanuele Zucca, Prof         
Kantonsspital Luzern Recruiting
Luzerne, Switzerland, CH-6000
Contact: Thilo Zander, MD    +41 41 205 11 11   
Principal Investigator: Thilo Zander, MD         
Kantonsspital - St. Gallen Recruiting
St. Gallen, Switzerland, CH-9007
Contact: Martin Fehr, MD    +41 71 494 11 11   
Principal Investigator: martin fehr, MD         
Klinik Hirslanden Recruiting
Zurich, Switzerland, CH-8032
Contact: Christoph Renner, Prof    +41 43 344 33 44   
Principal Investigator: Christoph Hirslanden, Prof         
Onkozentrum - Klinik Im Park Recruiting
Zürich, Switzerland, 8038
Contact: Christoph Renner, Prof    +41 43 344 33 33   
Principal Investigator: Christoph Renner, Prof         
UniversitätsSpital Zürich Recruiting
Zürich, Switzerland, 8091
Contact: Thorsten Zenz, Prof    +41 44 255 94 96   
Principal Investigator: Thorsten Zenz, Prof         
Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
European Mantle Cell Lymphoma Network
Layout table for investigator information
Study Chair: Urban Novak, PD Dr. med. University Hospital Bern - Inselspital

Layout table for additonal information
Responsible Party: Swiss Group for Clinical Cancer Research Identifier: NCT02356458     History of Changes
Other Study ID Numbers: SAKK 36/13
2014-003893-17 ( EudraCT Number )
SNCTP000001235 ( Other Identifier: Swiss National Clinical Trial Portal )
First Posted: February 5, 2015    Key Record Dates
Last Update Posted: April 9, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Swiss Group for Clinical Cancer Research:
Mantle cell lymphoma
Ibrutinib Imbruvica
Bortezomib Velcade
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents